Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

CAPTURE Data Should Help Drive Soltamox Sales At DARA Bio

On February 25, 2014, DARA BioScience, Inc. (DARA) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to KRN5500 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics. We see this as positive news for DARA, especially since we've been talking about this since late November 2012 when the application was first filed! We encourage investors to view our recent Seeking-Alpha article on KRN5500 to get a sense on just what gaining ODD status for the drug means.

But more important than gaining ODD status on KRN5500, and central to our thesis on the stock, is the potential for top-line acceleration and DARA's burgeoning specialty...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details